Program Urges Increased Cancer Data Sharing
Stakeholders of Project Data Sphere authored a Sounding Board article in the New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers.
In an example of the continued push among industry, academia, government, and hospitals to share more clinical research data, stakeholders of Project Data Sphere, LLC (PDS), a non-profit initiative of the CEO Roundtable on Cancer's Life Sciences Consortium, authored a Sounding Board article in this week’s New England Journal of Medicine urging the responsible sharing of cancer trial data with global researchers. Allowing researchers direct data access, the authors say, is critical to eliminating siloes and expanding discoveries and learnings in oncology R&D for the benefit of patients.
To that end, PDS has its own open-access cancer data platform, housing a free digital library of data. The platform, launched in 2014, allows researchers to download, share, integrate, and analyze patient data, while keeping patient anonymity intact. Presently, the platform includes 72 datasets resulting from nearly 42,000 patient lives, and PDS intends to expand the data and optimize the sharing of learned resources for trial participants. The platform can be found here: www.ProjectDataSphere.org
The CEO Roundtable on Cancer, comprised of top leaders from more than 30 U.S. companies, was founded by President Bush in 2001.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
Landmark Phase III Trial Shows Keytruda Significantly Improves Event-Free Survival in LA-HNSCC
April 28th 2025Interim KEYNOTE-689 trial data show that perioperative Keytruda significantly lowers the risk of disease progression or recurrence in resectable, locally advanced head and neck squamous cell carcinoma, marking the first major clinical advance for this patient population in more than two decades.
